Precision BioSciences, Inc.

CMN Weekly (6 March 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

FDA Clears ARCUS Editor for Duchenne Hot-spot

The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...

CMN Weekly (13 February 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (14 November 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (10 October 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (19 September 2025) - Your Weekly...

Some of the best links we picked up around the internet

ARCUS Gene Editor Shows Promise Against Hepatitis...

Precision BioSciences presented encouraging early clinical results from its PBGENE-HBV programme at the 6th International Coalition to Eliminate HBV...

CMN Weekly (12 September 2025) - Your Weekly...

Some of the best links we picked up around the internet

Precision BioSciences, Inc.

Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

B-Cell Non-Hodgkin Lymphoma, NHL, (NCT04649112)
Sponsors:
Precision BioSciences Inc.

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03666000)
Sponsors:
Imugene Limited

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Lymphoma and Leukaemia, (NCT04030195)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine